Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials.

ABSTRACT:

Background and aims

Bempedoic Acid (BA) is a novel Lipid-Lowering Therapy (LLT). We performed a systematic review and meta-analysis to assess the efficacy and safety of BA in patients with hypercholesterolemia.

Methods

PubMed, Scopus, and Cochrane library databases were searched for randomised controlled trials evaluating the efficacy and/or safety of BA compared with placebo. Trials investigating dosages other than 180 mg/die were excluded. Major adverse cardiovascular events (MACE) were the primary efficacy endpoint. LDL-cholesterol reduction was the primary laboratory endpoint. Pre-specified safety endpoints included muscle-related adverse events, new-onset diabetes, and gout. The protocol was registered on PROSPERO (temporary ID:399,867).

Results

Study search iden

SUBMITTER: De Filippo O 

PROVIDER: S-EPMC10685600 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature